While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

The mechanism of GLP-1 agonists is straightforward. They mimic the effects of the naturally occurring hormone, GLP-1, which regulates blood sugar and appetite in the body. While they are highly ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

Synthetic biology (SynBio) has stopped dividing itself by categories — red, yellow, green, blue, white — medicine, environment, agriculture, water, and industry —and is now united as one movement, ...

Mapping how T-cell leukemia develops, a team of researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital, University College London, and Addenbrooke’s Hospital in the U.K. identified ...

If you thought September was huge for M&As in the biopharma space, you didn’t see October coming. Nine major M&As were signed, with most of them being multi-billion-dollar deals in various therapeutic ...

The global biotech industry is booming, and by 2025 it will reach an estimated market worth of $729B. But while great innovation is driven by emerging biotechs, these companies often lack resources, ...

Recombinant protein expression lies at the heart of modern biotechnology and biopharmaceutical production. For decades, the field has relied primarily on two established expression systems namely ...

Today, AAVantgarde Bio raises $141 million (€122 million) in a series B round to advance its gene therapy programs for inherited eye diseases, marking one of Europe’s largest private financings in ...